.png){kind=icon}
.png){kind=icon}
Return
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
.png){kind=icon}
PRE
AI
DOI：10.1038/s41375-018-0013-4.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable markers for progression are critical for the development of potential therapeutic interventions. We retrospectively evaluated the predictive value of the evolving pattern of serum M-protein among other progression risk factors in 206 patients with SMM diagnosed between 1973 and 2012. Median time from recognition of evolving type to progression into symptomatic MM was 1.1 years (95% CI 0.5-2.0) and progression rate at 3 years was 71%. Development of the evolving type drastically worsened the prognostic estimation made at diagnosis for every covariate predictive of progression (serum M-protein size, bone marrow plasma cell infiltration, immunoparesis and Mayo Clinic risk). On average, the hazard ratio for progression to symptomatic MM increased to 5.1 (95% CI 3.4-7.6) after recognition of the evolving type. In conclusion, in patients with SMM the evolving pattern accurately predicts the risk of early progression to symptomatic disease, thereby allowing the identification of ultra-high risk patients who would be candidates for immediate therapy.
Keywords:
MULTIPARAMETER FLOW-CYTOMETRY
MARROW PLASMA-CELLS
MONOCLONAL GAMMOPATHY
UNDETERMINED SIGNIFICANCE
RISK
PREDICTORS
CRITERIA
RECOGNITION
PROGNOSIS
DIAGNOSIS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
13.4
Papers:
1.1W
Citations:
3.1W
View more organizations